AIM:To investigate the value of combined detection of circulating cell-free DNA(cfDNA),a-fetal protein(AFP) and a L-fucosidase(AFU) for diagnosis of hepatocellular carcinoma(HCC).METHODS:Serum samples from 39 HCC pati...AIM:To investigate the value of combined detection of circulating cell-free DNA(cfDNA),a-fetal protein(AFP) and a L-fucosidase(AFU) for diagnosis of hepatocellular carcinoma(HCC).METHODS:Serum samples from 39 HCC patients and 45 normal controls were collected.Branched DNA(bDNA) was used to detect the level of cfDNA,and a receiver operating characteristic curve was employed to evaluate the diagnostic sensitivity,specificity,accuracy,positive predictive value,negative predictive value,positive likelihood ratio,negative likelihood ratio and Youden index,and to assess the diagnostic efficiency and their correlations with the clinicopathological features.AFP and AFU were detected by chemiluminescence and colorimetry,respectively.The significance of combined detection of the three biomarkers was discussed.RESULTS:cfDNA level was increased in 22 of the 39 HCC samples and in 2 of the 45 normal controls.cfDNA level in HCC samples was significantly higher than that in normal controls(P < 0.05).There were significant differences in sex and extra-and intrahepatic metastasis(P < 0.05).There was no significant correlation between cfDNA,AFP and AFU in the detection of HCC.The sensitivity of combined detection of cfDNA with one marker(AFP or AFU) and cfDNA with two markers(AFP and AFU) was 71.8%,87.2% and 89.7% vs 56.4%,53.8% and 66.7% for cfDNA,AFP and AFU used alone,respectively,the difference being statistically significant(P < 0.05).CONCLUSION:Quantitative analysis of cfDNA is sensitive and feasible,and the combined detection of cfDNA with AFP or AFU or both could improve the diagnostic sensitivity for HCC.展开更多
Colorectal cancer(CRC) is one of the most prevalent malignancies in the world. CRC-associated morbidity and mortality is continuously increasing, in part due to a lack of early detection. The existing screening tools ...Colorectal cancer(CRC) is one of the most prevalent malignancies in the world. CRC-associated morbidity and mortality is continuously increasing, in part due to a lack of early detection. The existing screening tools such as colonoscopy, are invasive and yet high cost, affecting the willingness of patients to participate in screening programs. In recent years, evidence is accumulating that the interaction of aberrant genetic and epigenetic modifications is the cornerstone for the CRC development and progression by alternating the function of tumor suppressor genes, DNA repair genes and oncogenes of colonic cells. Apart from the understanding of the underlying mechanism(s) of carcinogenesis, the aforementioned interaction has also allowed identification of clinical biomarkers, especially epigenetic, for the early detection and prognosis of cancer patients. One of the ways to detect these epigenetic biomarkers is the cell-free circulating DNA(circ DNA), a blood-based cancer diagnostic test, mainly focusing in the molecular alterations found in tumor cells, such as DNA mutations and DNA methylation.In this brief review, we epitomize the current knowledge on the research in circ DNA biomarkers-mainly focusing on DNA methylation-as potential blood-based tests for early detection of colorectal cancer and the challenges for validation and globally implementation of this emergent technology.展开更多
目的比较血循环肿瘤细胞(CTCs)、循环游离DNA(cf DNA)联合检测与传统肿瘤标志物糖蛋白抗原153(CA153)检测在辅助诊断乳腺癌中的应用价值。方法回顾性选择2017年1月到2019年6月在安徽省第二人民医院收治的82例被确诊的乳腺癌患者为乳腺癌...目的比较血循环肿瘤细胞(CTCs)、循环游离DNA(cf DNA)联合检测与传统肿瘤标志物糖蛋白抗原153(CA153)检测在辅助诊断乳腺癌中的应用价值。方法回顾性选择2017年1月到2019年6月在安徽省第二人民医院收治的82例被确诊的乳腺癌患者为乳腺癌组,选取同期收治的50例乳腺良性疾病患者为乳腺良性疾病组,50例于该院体检的健康女性为对照组。采用ROCHE化学发光仪检测血清CA153水平;采用qPCR检测血浆cf DNA基因水平(241 bp hTERT和100 bp hTERT)和完整性(241 bp hTERT/100 bp hTERT);采用Ce1l Search系统检测血CTCs;受试者工作曲线(ROC)分析血CA153、cf DNA与CTCs诊断乳腺癌的诊断价值。结果乳腺癌组患者的血CTCs阳性表达率为37. 80%,明显高于乳腺良性疾病组的16. 00%(P <0. 05),明显高于对照组的12. 00%(P <0. 05);乳腺癌组的血CA153、241 bp hTERT、100 bp hTERT、241 bp hTERT/100 bp hTERT水平均明显高于乳腺良性疾病组(P <0. 05),乳腺良性疾病组的血CA153、241 bp hTERT、100 bp hTERT、241 bp hTERT/100 bp h TERT水平均明显高于对照组(P <0. 05);ROC分析显示,血cf DNA 241 bp hTERT、100 bp hTERT、241 bp hTERT/100 bp hTERT以及三者联合诊断乳腺癌的曲线下面积(AUC)依次为0. 865、0. 725、0. 870和0. 950;血CTCs和CA153诊断乳腺癌的AUC为0. 609和0. 733,明显低于cf DNA诊断的0. 950。结论血cf DNA对乳腺癌具有较高的诊断价值,有望应用于乳腺癌患者的临床辅助诊断。展开更多
文摘AIM:To investigate the value of combined detection of circulating cell-free DNA(cfDNA),a-fetal protein(AFP) and a L-fucosidase(AFU) for diagnosis of hepatocellular carcinoma(HCC).METHODS:Serum samples from 39 HCC patients and 45 normal controls were collected.Branched DNA(bDNA) was used to detect the level of cfDNA,and a receiver operating characteristic curve was employed to evaluate the diagnostic sensitivity,specificity,accuracy,positive predictive value,negative predictive value,positive likelihood ratio,negative likelihood ratio and Youden index,and to assess the diagnostic efficiency and their correlations with the clinicopathological features.AFP and AFU were detected by chemiluminescence and colorimetry,respectively.The significance of combined detection of the three biomarkers was discussed.RESULTS:cfDNA level was increased in 22 of the 39 HCC samples and in 2 of the 45 normal controls.cfDNA level in HCC samples was significantly higher than that in normal controls(P < 0.05).There were significant differences in sex and extra-and intrahepatic metastasis(P < 0.05).There was no significant correlation between cfDNA,AFP and AFU in the detection of HCC.The sensitivity of combined detection of cfDNA with one marker(AFP or AFU) and cfDNA with two markers(AFP and AFU) was 71.8%,87.2% and 89.7% vs 56.4%,53.8% and 66.7% for cfDNA,AFP and AFU used alone,respectively,the difference being statistically significant(P < 0.05).CONCLUSION:Quantitative analysis of cfDNA is sensitive and feasible,and the combined detection of cfDNA with AFP or AFU or both could improve the diagnostic sensitivity for HCC.
文摘Colorectal cancer(CRC) is one of the most prevalent malignancies in the world. CRC-associated morbidity and mortality is continuously increasing, in part due to a lack of early detection. The existing screening tools such as colonoscopy, are invasive and yet high cost, affecting the willingness of patients to participate in screening programs. In recent years, evidence is accumulating that the interaction of aberrant genetic and epigenetic modifications is the cornerstone for the CRC development and progression by alternating the function of tumor suppressor genes, DNA repair genes and oncogenes of colonic cells. Apart from the understanding of the underlying mechanism(s) of carcinogenesis, the aforementioned interaction has also allowed identification of clinical biomarkers, especially epigenetic, for the early detection and prognosis of cancer patients. One of the ways to detect these epigenetic biomarkers is the cell-free circulating DNA(circ DNA), a blood-based cancer diagnostic test, mainly focusing in the molecular alterations found in tumor cells, such as DNA mutations and DNA methylation.In this brief review, we epitomize the current knowledge on the research in circ DNA biomarkers-mainly focusing on DNA methylation-as potential blood-based tests for early detection of colorectal cancer and the challenges for validation and globally implementation of this emergent technology.
文摘目的比较血循环肿瘤细胞(CTCs)、循环游离DNA(cf DNA)联合检测与传统肿瘤标志物糖蛋白抗原153(CA153)检测在辅助诊断乳腺癌中的应用价值。方法回顾性选择2017年1月到2019年6月在安徽省第二人民医院收治的82例被确诊的乳腺癌患者为乳腺癌组,选取同期收治的50例乳腺良性疾病患者为乳腺良性疾病组,50例于该院体检的健康女性为对照组。采用ROCHE化学发光仪检测血清CA153水平;采用qPCR检测血浆cf DNA基因水平(241 bp hTERT和100 bp hTERT)和完整性(241 bp hTERT/100 bp hTERT);采用Ce1l Search系统检测血CTCs;受试者工作曲线(ROC)分析血CA153、cf DNA与CTCs诊断乳腺癌的诊断价值。结果乳腺癌组患者的血CTCs阳性表达率为37. 80%,明显高于乳腺良性疾病组的16. 00%(P <0. 05),明显高于对照组的12. 00%(P <0. 05);乳腺癌组的血CA153、241 bp hTERT、100 bp hTERT、241 bp hTERT/100 bp hTERT水平均明显高于乳腺良性疾病组(P <0. 05),乳腺良性疾病组的血CA153、241 bp hTERT、100 bp hTERT、241 bp hTERT/100 bp h TERT水平均明显高于对照组(P <0. 05);ROC分析显示,血cf DNA 241 bp hTERT、100 bp hTERT、241 bp hTERT/100 bp hTERT以及三者联合诊断乳腺癌的曲线下面积(AUC)依次为0. 865、0. 725、0. 870和0. 950;血CTCs和CA153诊断乳腺癌的AUC为0. 609和0. 733,明显低于cf DNA诊断的0. 950。结论血cf DNA对乳腺癌具有较高的诊断价值,有望应用于乳腺癌患者的临床辅助诊断。
